October 06, Colombo (LNW): A homegrown nutraceutical product, designed to target cancer stem cells, is gaining both domestic acclaim and international interest, with export revenues projected to reach approximately two million US dollars by the year 2027.
The development represents a promising intersection between modern science and natural therapeutics in Sri Lanka’s ongoing contribution to global health innovation.
The formulation, first introduced to the local market three years ago, has since cultivated a strong user base. Early adopters have reported notable improvements in overall wellbeing, prompting growing confidence in its potential to support those undergoing cancer treatment.
Although the product is not classified as a pharmaceutical drug, its formulation has been carefully designed to act as a complementary therapy in oncology care.
According to Professor Sameera R. Samarakoon of the Institute of Biochemistry, Molecular Biology and Biotechnology at the University of Colombo, the primary objective was to create a scientifically grounded supplement that offers support beyond conventional treatment.
“Cancer is addressed through a variety of interventions—ranging from surgery and chemotherapy to radiotherapy, targeted agents, and immunotherapy,” he stated. “Our aim was to develop a compound that addresses cancer stem cells, which are often implicated in relapse and treatment resistance, while enhancing quality of life.”
He added that the nutraceutical may also reduce the harsh side effects associated with mainstream therapies. “Many patients undergoing treatment suffer from toxicity-related complications. If we can ease that burden with a safe, adjunctive supplement, we’re not only treating the illness but also improving the journey through it.”
A consumer survey conducted by the University of Kelaniya in the previous year, involving more than 300 individuals, revealed a 93 percent satisfaction rate with the product—an encouraging indicator of its real-world impact.
Respondents reported perceived benefits such as improved energy levels, appetite regulation, and general resilience during ongoing cancer therapies.
The development process has been collaborative and interdisciplinary. Current preclinical and clinical trials are being conducted in conjunction with several academic institutions, including the University of Ruhuna and the Faculty of Indigenous Medicine at the University of Colombo. These partnerships seek to deepen scientific understanding of the compound’s bioactivity and safety profile.
Professor Samarakoon also confirmed that discussions are underway with international research bodies to undertake further validation studies. The intention is to build a robust portfolio of evidence that meets global standards and paves the way for international recognition and regulatory acceptance.
“This is not about replacing conventional treatments, but about offering patients and healthcare providers an additional, evidence-informed option,” he remarked. “With continued research and strategic global collaboration, we believe this Sri Lankan innovation could gain a place in the wider spectrum of integrative oncology.”
